# US 2016/0354460 A1 · Live-attenuated virus and methods of production and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354460 A1
- Document ID: US20160354460A1
- Status: Published application
- Kind: A1
- Application number: 15/174,348
- Filed: 2016-06-06
- Published: 2016-12-08
- Earliest claimed: 2015-06-04
- Assignees: The University of Hong Kong
- Applicants: The University of Hong Kong
- Inventors: Lit Man Poon; Lok Yan Fan
- Web page: https://patentgrep.com/patent/US20160354460A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16162: by genetic engineering
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins. The live-attenuated viruses display unaltered replication in avian hosts for propagation, but attenuated replication in mammalian hosts, when compared to the replication of the parental virus. The live-attenuated viruses in a form of improved vaccines can be used to elicit protective immune responses.

## Claims

### Claim 1

A live-attenuated virus comprising a genome genetically engineered from a wild type virus to have mutated codons having an avian viral codon usage bias, the mutated codons having an avian viral codon usage bias present at conserved sites at the amino acid level and absent from genomic regions involving packaging or splicing, or overlapping reading frames encoding multiple proteins.

### Claim 2 (depends on 1)

The live-attenuated virus of claim 1, wherein the mutated codons having an avian viral codon usage bias are synonymous substitutions.

### Claim 3 (depends on 1)

The live-attenuated virus of claim 1, wherein the mutated codons having an avian viral codon usage bias are silent mutations.

### Claim 4 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus does not have any amino acid mutations relative to the wild type virus.

### Claim 5 (depends on 1)

The live-attenuated virus of claim 1, wherein the mutated codons having an avian viral codon usage bias are randomly but evenly distributed in the genome.

### Claim 6 (depends on 1)

The live-attenuated virus of claim 1, wherein the mutated codons having an avian viral codon usage bias are present in at least one gene, in at least two genes, in at least three genes, in at least four genes, in at least five genes, in at least six genes, in at least seven genes, or in at least eight genes.

### Claim 7 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus has slower replication in a mammalian host but not in an avian host, when compared to the replication of the wild type virus in the respective hosts.

### Claim 8 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus produces antibody-mediated immunity similar to that produced by the wild type virus.

### Claim 9 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus produces cell-mediated immunity similar to that produced by the wild type virus.

### Claim 10 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus produces antibody-mediated immunity and cell-mediated immunity similar to that produced by the wild type virus.

### Claim 11 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus replicates at substantially the same rate at 33° C. and at 37° C.

### Claim 12 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus produces a protective immune response in a mammalian host against homologous and heterologous viral challenges.

### Claim 13 (depends on 1)

The live-attenuated virus of claim 1, wherein the wild type virus is influenza type A or influenza type B.

### Claim 14 (depends on 13)

The live-attenuated virus of claim 13, wherein the live-attenuated virus is 8-mut.

### Claim 15 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus does not have any temperature-sensitive mutations relative to the wild type virus.

### Claim 16 (depends on 1)

The live-attenuated virus of claim 1, wherein the live-attenuated virus is a master strain.

### Claim 17 (depends on 1)

A method of making the live-attenuated virus of claim 1, the method comprising:
identifying regions of conserved sites at the amino acid level in the genome of the wild type virus;
identifying codons in the conserved sites of the wild type virus that do not have avian viral codon usage bias;
mutating one or more of the identified codons of the wild type virus that do not have avian viral codon usage bias into codons having avian viral codon usage bias to produce mutated codons having an avian viral codon usage bias.

### Claim 18 (depends on 17)

The method of claim 17, further comprising producing the live-attenuated virus by contacting a host cell with one or more nucleic acid regions collectively forming the genome of the live-attenuated virus, wherein at least one of the regions comprises the mutated codons.

### Claim 19 (depends on 17)

The method of claim 17, wherein at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight regions comprise the mutated codons.

### Claim 20 (depends on 1)

A vaccine composition comprising the live-attenuated virus of claim 1.

### Claim 21 (depends on 20)

The vaccine composition of claim 20, further comprising a carrier.

### Claim 22 (depends on 21)

The vaccine composition of claim 21, further comprising an adjuvant.

### Claim 23 (depends on 1)

A method comprising administering to a subject in need thereof an effective dose of the live-attenuated virus of claim 1.
